Similar to our previous trials, this was accompanied by significantly higher frequencies of tumour peptide‐specific CD8+ T cells (H‐2Kb‐Trp2+) in the blood of ACM‐Trp2 + ACM‐CpG‐treated mice on day 17 and day 33 p.i., as compared to the other treatment groups (Figure 4D,E). This evidence concerns the gene CD8A and neoplasm.